Date: 2021/09/29	
Your Name: Qinggui Chen	
Manuscript Title: miR-873-5p targets the THUMPD1 to	inhibit gastric cancer cell behavior and chemoresistance
Manuscript number (if known):_	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shanghai Tongshu Biotechnology Co., Ltd	technical support
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	/ _None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	/ None	
	testimony		
7	Support for attending meetings and/or travel	/ None	
8	Patents planned, issued or	✓ _None	
	pending		
9	Participation on a Data	/ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	/ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	/ None	
12	Receipt of equipment,	/ None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	✓ None	
	financial interests		
			'
DI		. (I) - L - (! - L L ! - L - C	. U

All authors reported that they received technical support from Shanghai Tongshu Biotechnology Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement:

Date:2021/09/29	
Your Name:Li Li	1
Manuscript Title:	miR-873-5p targets the THUMPD1 to inhibit gastric cancer cell behavior and chemoresistance
Manuscript number	(if known):_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present manuscript (e.g., funding,	Shanghai Tongshu Biotechnology Co., Ltd	technical support
	provision of study materials, medical writing, article		
	processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	v None	
4	Consulting fees	v None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	/ None	
	testimony		
7	Support for attending meetings and/or travel	/ None	
8	Patents planned, issued or	✓ _None	
	pending		
9	Participation on a Data	/ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	/ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	/ None	
12	Receipt of equipment,	/ None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	✓ None	
	financial interests		
			'
DI		. (I) - L - (! - L L ! - L - C	. U

All authors reported that they received technical support from Shanghai Tongshu Biotechnology Co., Lt	ːd.

Please place an "X" next to the following statement to indicate your agreement:

Date:2021/09/2	9
Your Name: Boli	ang Xiong
Manuscript Title:	miR-873-5p targets the THUMPD1 to inhibit gastric cancer cell behavior and chemoresistance
Manuscript number	(if known):_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shanghai Tongshu Biotechnology Co., Ltd	technical support
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	V None	
3	Royalties or licenses	None	
4	Consulting fees	/ None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	/ None	
	testimony		
7	Support for attending meetings and/or travel	/ None	
8	Patents planned, issued or	✓ _None	
	pending		
9	Participation on a Data	/ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	/ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	/ None	
12	Receipt of equipment,	/ None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	✓ None	
	financial interests		
			'
DI		. (I) - L - (! - L L ! - L - C	. U

All authors reported that they received technical support from Shanghai Tongshu Biotechnology Co., Ltd.	

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021/09/29	
Your Name: Wensheng Yang	
Manuscript Title: miR-873-5p targets the THUMPD1 to	inhibit gastric cancer cell behavior and chemoresistance
Manuscript number (if known):_	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shanghai Tongshu Biotechnology Co., Ltd	technical support
2	Constant and a state of the state	Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	/ None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	/ None	
	testimony		
7	Support for attending meetings and/or travel	/ None	
8	Patents planned, issued or	✓ _None	
	pending		
9	Participation on a Data	/ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	/ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	/ None	
12	Receipt of equipment,	/ None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	✓ None	
	financial interests		
			'
DI		. (I) - L - (! - L L ! - L - C	. U

All a	thors reported that they received technical support from Shanghai Tongshu Biotechnology Co., Ltd.	

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021/09/29	
Your Name: <u>Junli Huang</u>	
Manuscript Title: miR-873-5p targets the THUMPD1	o inhibit gastric cancer cell behavior and chemoresistance
Manuscript number (if known):_	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shanghai Tongshu Biotechnology Co., Ltd	technical support
2	Constant and a state of the state	Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	/ None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	/ None	
	testimony		
7	Support for attending meetings and/or travel	/ None	
8	Patents planned, issued or	✓ _None	
	pending		
9	Participation on a Data	/ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	/ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	/ None	
12	Receipt of equipment,	/ None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	✓ None	
	financial interests		
			'
DI		. (I) - L - (! - L L ! - L - C	. U

All authors reported that they received technical support from Shanghai Tongshu Biotechnology Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021/09/2	9			
Your Na	ame:Hui	bo Shi			
Manus	cript Title:	miR-873-5p targets the THUMPD1 to	inhibit gastric cancer	cell behavior and chemoresistar	1ce
Manus	cript number	(if known):_			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shanghai Tongshu Biotechnology Co., Ltd	technical support
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past✓_ None	36 months
3	Royalties or licenses	None	
4	Consulting fees	/ None	

			-
5	Payment or honoraria for	/ None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	v None	
	testimony		
7	Support for attending meetings and/or travel	V None	
8	Patents planned, issued or	/ _None	
	pending		
9	Participation on a Data	✓ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	/ None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	✓ None	
11	Stock of Stock options	V None	
12	Receipt of equipment,	✓ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	✓ None	
	financial interests		

All authors reported that they received technical support from Shanghai Tongshu Biotechnology Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>2021/09/29</u>	
Your Name: Zhenfa Wang	
Manuscript Title: miR-873-5p targets the THUMPD1 t	o inhibit gastric cancer cell behavior and chemoresistance
Manuscript number (if known):_	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shanghai Tongshu Biotechnology Co., Ltd	technical support
2	Constant and a state of the state	Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	/ None	

5	Payment or honoraria for	None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	/ None		
	testimony			
7	Support for attending meetings and/or travel	/ None		
8	Patents planned, issued or	✓ _None		
	pending			
9	Participation on a Data	/ None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	/ None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	/ None		
12	Receipt of equipment,	/ None		
	materials, drugs, medical writing, gifts or other			
	services			
13	Other financial or non-	✓ None		
	financial interests			
			'	
DI		. (I) . L . (! L ! L (. U	

All authors reported that they received technical support from Shanghai Tongshu Biotechnology Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement: